Stockreport

uniQure Announces Updated, Long-Term Clinical Data from Ongoing Phase I/II Trial of AMT-060 In Patients with Severe Hemophilia B

uniQure N.V. - Ordinary Shares  (QURE) 
Last uniqure n.v. - ordinary shares earnings: 4/29 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: uniqure.com/investors-newsroom/overview.php
PDF – Clinical Benefit Maintained in All Patients, with Durable Increases in FIX Clotting Activity at Up to Two Years of Follow-Up – – Second Dose Cohort Demonstrated 89% R [Read more]